SCHEMBL23979475

SCHEMBL23979475

CCCCCCC(=O)NCc1ccc2nc(C)n(C3CCCC(=O)NC3=O)c(=O)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 3/20 0.49
CRBN Q96SW2 3/20 0.49
TRPV1 Q8NER1 3/20 0.41
TNF P01375 1/20 0.39
IL1B P01584 1/20 0.39
IKZF3 Q9UKT9 1/20 0.39
EPHX2 P34913 2/20 0.39
ENPP2 Q13822 1/20 0.38
HPGD P15428 2/20 0.38
ALOX15 P16050 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18595132 0.95 CRBN (0.55) DDB1CRBNTRPV1TNFIL1B
SCHEMBL26192453 0.95 CRBN (0.55) DDB1CRBNTRPV1TNFIL1B
SCHEMBL13806967 0.95 CRBN (0.55) DDB1CRBNTRPV1TNFIL1B
SCHEMBL16221487 0.94 CRBN (0.56) DDB1CRBNTRPV1TNFIL1B
SCHEMBL23979598 0.91 CRBN (0.49) DDB1CRBNTNFIL1BIKZF3
SCHEMBL12638502 0.89 DDB1 (0.45) DDB1CRBNTRPV1EPHX2ENPP2
SCHEMBL15362536 0.89 DDB1 (0.45) DDB1CRBNTRPV1EPHX2ENPP2
SCHEMBL16218183 0.88 DDB1 (0.46) DDB1CRBNTRPV1EPHX2ENPP2
SCHEMBL3653428 0.85 CRBN (0.55) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23980066 0.85 DDB1 (0.54) DDB1CRBNTNFIL1BIKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885TRPV1 2606/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885TRPV1 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.